Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting

BACKGROUND: KEYNOTE-181, ATTRACTION-3, and ESCORT trials have opened the era of programmed death 1 (PD-1) inhibitors in the second-line therapy for esophageal squamous cell carcinoma (ESCC). There is no head-to-head comparison of pembrolizumab vs. nivolumab vs. camrelizumab in the second-line settin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yi-Xin, Chen, Ping, Sun, Yu-Ting, Zhang, Bei, Qiu, Miao-Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490758/
https://www.ncbi.nlm.nih.gov/pubmed/34621668
http://dx.doi.org/10.3389/fonc.2021.698732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490758/
https://www.ncbi.nlm.nih.gov/pubmed/34621668
http://dx.doi.org/10.3389/fonc.2021.698732

Ejemplares similares